BCM
ELGX

BlueCrest Capital Management’s Endologix Inc ELGX Stock Holding History

BlueCrest Capital Management’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,160
Closed -$115K – 1248
2015
Q4 		$115K Buy
+1,160
New +$124K ﹤0.01% 911

Other funds holding ELGX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SI
Stephens Inc Little Rock, Arkansas $8.93B AUM 25.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

BlueCrest Capital Management's ELGX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Endologix Inc (ELGX) in Q4 2018, closing a stake of 10,922 shares — an estimated $209K sold.

BlueCrest Capital Management first reported a position in ELGX in Q2 2017 and held it in 4 quarters. The position peaked at $417K in Q1 2018. 99 funds tracked by Wall St. Rank hold ELGX as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Endologix Inc position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,922 Endologix Inc shares in Q4 2018, an estimated $209K.
  • BlueCrest Capital Management first reported a position in Endologix Inc in Q2 2017 and held it in 4 quarters.
  • BlueCrest Capital Management's Endologix Inc position peaked at $417K in Q1 2018.
  • 99 funds tracked by Wall St. Rank held Endologix Inc as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.